Mereo BioPharma
London, United Kingdom

Mereo BioPharma develops and commercialises innovative therapeutics addressing oncology and rare diseases. It also has specialty pharmaceutical products that it will partner. The assets are acquired or licensed in at clinical stages from large pharmaceutical companies. The portfolio consists of six compounds that are in clinical development.

Investment Perspective

Mereo BioPharma is set to progress its promising anti-TIGIT antibody, etigilimab, into Phase Ib/II trials for multiple solid tumour types in Q420. The study will focus on less common tumour types, including several rare cancers, and employ a flexible design to respond rapidly if data is promising. Phase II alvelestat results are expected in H221 for AATD, with Phase Ib data for COVID-19 likely in mid-21. A partner to progress setrusumab (osteogenesis imperfecta, OI) into the Phase III registration trial has been announced. Similarly, partnering news for the non-core assets, leflutrozole and acumapimod, is anticipated. We suspend our valuation and forecasts with the intention of reinstating them as soon as practicable.

Market information



Setrusumab partnered with Ultragenyx
Lighthouse | 18 Dec 2020
Targeting TIGIT thoughtfully
Update | 09 Dec 2020
H120 results and corporate review
Update | 12 Oct 2020

Recent News

Pricing of $100m Public Offering of ADS
10 Feb 2021
Setrusumab partnership with Ultragenyx
17 Dec 2020
Update on AIM delisting and agreements with SVB and Kreos Capital
15 Dec 2020
Appointment of SVP of Clinical Development
23 Nov 2020